{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:12:08Z","timestamp":1789823528500,"version":"4.0.1"},"reference-count":141,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82020108004"],"award-info":[{"award-number":["82020108004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100235"],"award-info":[{"award-number":["82100235"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100226"],"award-info":[{"award-number":["82100226"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFA1103300"],"award-info":[{"award-number":["2022YFA1103300"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014869","name":"Army Medical University Xinqiao Hospital","doi-asserted-by":"publisher","award":["2022YQB004"],"award-info":[{"award-number":["2022YQB004"]}],"id":[{"id":"10.13039\/501100014869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2022NSCQ-MSX1060"],"award-info":[{"award-number":["CSTB2022NSCQ-MSX1060"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1103304"],"award-info":[{"award-number":["2022YFA1103304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.heliyon.2024.e38460","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T16:46:02Z","timestamp":1727282762000},"page":"e38460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recent advances and research progress regarding monoclonal antibodies for chronic graft-versus-host disease"],"prefix":"10.1016","volume":"10","author":[{"given":"Shiqin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guancui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxiao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-2832","authenticated-orcid":false,"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from the Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e38460_bib2","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/CM9.0000000000002235","article-title":"Current status and prospects of hematopoietic stem cell transplantation in China","volume":"135","author":"Wang","year":"2022","journal-title":"CHINESE MED J-PEKING"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e38460_bib3","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38460_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e38460_bib5","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib6","first-page":"648","article-title":"Updates in chronic graft-versus-host disease","volume":"2021","author":"Hamilton","year":"2021","journal-title":"HEMATOL-AM SOC HEMAT"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38460_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the national Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"9674","key":"10.1016\/j.heliyon.2024.e38460_bib8","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet (N. Am. Ed.)"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.34750","article-title":"Evaluation of ruxolitinib for steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation","volume":"4","author":"Wu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.heliyon.2024.e38460_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954268","article-title":"Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: a meta-analysis","volume":"13","author":"Fan","year":"2022","journal-title":"Front. Immunol."},{"issue":"26","key":"10.1016\/j.heliyon.2024.e38460_bib11","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"NEW ENGL J MED"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38460_bib12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA approves 100th monoclonal antibody product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"SIGNAL TRANSDUCT TAR"},{"issue":"20","key":"10.1016\/j.heliyon.2024.e38460_bib14","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2017-05-786137","article-title":"Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study","volume":"130","author":"Malard","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38460_bib22","first-page":"511","article-title":"Long-term clinical outcomes and B cell immune reconstitution following allo-HCT with prophylactic, post-transplant rituximab","volume":"30","author":"Kennedy","year":"2024","journal-title":"TRANSPL CELL THER"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38460_bib23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12288-017-0783-2","article-title":"Protective effect of rituximab in chronic graft-versus-host disease occurrence in allogeneic transplant patients with Epstein barr virus viremia","volume":"33","author":"Ji","year":"2017","journal-title":"INDIAN J HEMATOL BLO"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41409-023-02171-5","article-title":"Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial","volume":"59","author":"Cabrero","year":"2024","journal-title":"BONE MARROW TRANSPL"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e38460_bib59","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1182\/bloodadvances.2023010973","article-title":"High-dose alemtuzumab-cyclosporine vs tacrolimus-methotrexate-sirolimus for chronic graft-versus-host disease prevention","volume":"8","author":"Holtzman","year":"2024","journal-title":"BLOOD ADV"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38460_bib60","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.16200","article-title":"Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival","volume":"188","author":"Finazzi","year":"2020","journal-title":"BRIT J HAEMATOL"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38460_bib61","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bjh.17418","article-title":"Excellent overall and chronic graft-versus-host-disease-free event-free survival in Fanconi anaemia patients undergoing matched related- and unrelated-donor bone marrow transplantation using alemtuzumab-Flu-Cy: the UK experience","volume":"193","author":"Bernard","year":"2021","journal-title":"BRIT J HAEMATOL"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib62","first-page":"311","volume":"30","author":"Lum","year":"2024","journal-title":"TRANSPL CELL THER"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38460_bib70","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-019-03662-6","article-title":"Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients","volume":"98","author":"Gaudio","year":"2019","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib71","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.15152","article-title":"Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party","volume":"181","author":"Bazarbachi","year":"2018","journal-title":"BRIT J HAEMATOL"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib81","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3324\/haematol.2022.281309","article-title":"Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination","volume":"108","author":"Chhabra","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38460_bib48","first-page":"121","article-title":"Targeted therapy with venetoclax and daratumumab as part of HSCT preparative regimen in children with chemorefractory acute myeloid leukemia","volume":"29","author":"Klimentova","year":"2023","journal-title":"TRANSPL CELL THER"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38460_bib50","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.clml.2020.01.010","article-title":"Graft-versus-host disease in multiple myeloma patients treated with daratumumab after allogeneic transplantation","volume":"20","author":"Nikolaenko","year":"2020","journal-title":"CL LYMPH MYELOM LEUK"},{"key":"10.1016\/j.heliyon.2024.e38460_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1017850","article-title":"Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38460_bib30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1078-0432.CCR-15-1443","article-title":"A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation","volume":"22","author":"Arai","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38460_bib31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/s41409-018-0158-9","article-title":"Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib","volume":"53","author":"van der Wagen","year":"2018","journal-title":"BONE MARROW TRANSPL"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e38460_bib26","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.bbmt.2015.04.023","article-title":"Corticosteroid-free primary treatment of chronic extensive graft-versus-host disease incorporating rituximab","volume":"21","author":"Solomon","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38460_bib29","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s00277-019-03768-x","article-title":"Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease-single center experience","volume":"98","author":"Klobuch","year":"2019","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38460_bib28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00408-017-0051-0","article-title":"Effect of rituximab on pulmonary function in bronchiolitis obliterans syndrome due to graft-versus-host-disease","volume":"195","author":"Brownback","year":"2017","journal-title":"Lung"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38460_bib27","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41409-018-0399-7","article-title":"Safety and efficacy of rituximab-based first line treatment of chronic GVHD","volume":"54","author":"Solomon","year":"2019","journal-title":"BONE MARROW TRANSPL"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38460_bib33","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.bbmt.2015.03.014","article-title":"Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results","volume":"21","author":"Pidala","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/bloodadvances.2021005552","article-title":"A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease","volume":"6","author":"Lazaryan","year":"2022","journal-title":"BLOOD ADV"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38460_bib65","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbmt.2013.02.009","article-title":"Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease","volume":"19","author":"Nikiforow","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e38460_bib73","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.bbmt.2018.05.012","article-title":"Phase I trial of brentuximab vedotin for steroid-refractory chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"24","author":"DeFilipp","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38460_bib82","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00277-020-03968-w","article-title":"IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"99","author":"Kattner","year":"2020","journal-title":"Ann. Hematol."},{"issue":"3, Supplement","key":"10.1016\/j.heliyon.2024.e38460_bib83","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.bbmt.2017.12.174","volume":"24","author":"Beebe","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.heliyon.2024.e38460_bib119","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","author":"Kitko","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun Highlights"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38460_bib16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.coi.2008.05.011","article-title":"Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies","volume":"20","author":"Taylor","year":"2008","journal-title":"Curr. Opin. Immunol."},{"issue":"29","key":"10.1016\/j.heliyon.2024.e38460_bib17","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.2217\/fon-2017-0275","article-title":"The use of ofatumumab in the treatment of B-cell malignancies","volume":"13","author":"Soe","year":"2017","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38460_bib19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.bbmt.2014.04.028","article-title":"Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects","volume":"20","author":"Johnston","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38460_bib20","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2013-04-495895","article-title":"Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial","volume":"122","author":"Cutler","year":"2013","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.heliyon.2024.e38460_bib21","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1182\/blood-2011-12-395970","article-title":"Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence","volume":"119","author":"Arai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e38460_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2023-180142","article-title":"Effective prevention of steroid-requiring chronic graft-vs.-host disease with B cell depletion: a randomized, placebo-controlled trial","volume":"142","author":"Cutler","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib32","article-title":"Chronic graft-versus-host-disease-related polymyositis: a 17-months-old child with a rare and late complication of haematopoietic stem cell transplantation","volume":"12","author":"Chinello","year":"2020","journal-title":"MEDITERR J HEMATOL I"},{"issue":"20","key":"10.1016\/j.heliyon.2024.e38460_bib35","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-07-1290","article-title":"High levels of B-cell activating factor in patients with active chronic graft-versus-host disease","volume":"13","author":"Sarantopoulos","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38460_bib36","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/bmt.2017.73","article-title":"B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality","volume":"52","author":"Saliba","year":"2017","journal-title":"BONE MARROW TRANSPL"},{"issue":"18","key":"10.1016\/j.heliyon.2024.e38460_bib37","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1182\/blood.2020008040","article-title":"BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation","volume":"137","author":"Jia","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e38460_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.995149","article-title":"BAFF blockade attenuates acute graft-versus-host disease directly via the dual regulation of T- and B-cell homeostasis","volume":"13","author":"Jeon","year":"2022","journal-title":"Front. Immunol."},{"issue":"9767","key":"10.1016\/j.heliyon.2024.e38460_bib39","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet (N. Am. Ed.)"},{"key":"10.1016\/j.heliyon.2024.e38460_bib40","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1182\/blood-2021-146778","article-title":"Use of belimumab for prophylaxis of chronic graft-versus-host disease","volume":"138","author":"Pusic","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e38460_bib41","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1177\/0961203318777116","article-title":"Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL","volume":"27","author":"Parodis","year":"2018","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38460_bib42","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40744-020-00212-9","article-title":"Systemic lupus erythematosus (SLE) therapy: the old and the new","volume":"7","author":"Basta","year":"2020","journal-title":"RHEUMATOL THER"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38460_bib44","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1053\/jhep.2000.7713","article-title":"Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver","volume":"31","author":"Golden-Mason","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e38460_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.785774","article-title":"Daratumumab prevents experimental xenogeneic graft-versus-host disease by skewing proportions of T cell functional subsets and inhibiting T cell activation and migration","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib46","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.heliyon.2024.e38460_bib47","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"BLOOD ADV"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib49","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41409-021-01560-y","article-title":"Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT","volume":"57","author":"Vincent","year":"2022","journal-title":"BONE MARROW TRANSPL"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38460_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14263","article-title":"A case of treatment-resistant membranous nephropathy associated with graft versus host disease successfully treated with daratumumab","volume":"26","author":"Benoit","year":"2022","journal-title":"Pediatr. Transplant."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib52","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of Campath-1H antibody on human hematopoietic progenitors in vitro","volume":"82","author":"Gilleece","year":"1993","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib53","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41598-023-50416-6","article-title":"The role of graft T-cell size in patients receiving alemtuzumab serotherapy for non-malignant disorders: results of an institutional protocol","volume":"14","author":"Pandrowala","year":"2024","journal-title":"SCI REP-UK"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38460_bib54","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1182\/blood-2003-02-0489","article-title":"Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation","volume":"102","author":"Antin","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib55","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V99.3.1071","article-title":"Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen","volume":"99","author":"Chakraverty","year":"2002","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e38460_bib56","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2010-05-286856","article-title":"Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution","volume":"116","author":"Chakraverty","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38460_bib57","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/bmt.2010.308","article-title":"Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia","volume":"46","author":"Spyridonidis","year":"2011","journal-title":"BONE MARROW TRANSPL"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38460_bib58","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bbmt.2017.02.007","article-title":"Impact of alemtuzumab scheduling on graft-versus-host disease after unrelated donor fludarabine and melphalan allografts","volume":"23","author":"Green","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.heliyon.2024.e38460_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100772","article-title":"Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies","volume":"47","author":"Iftikhar","year":"2021","journal-title":"Blood Rev."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38460_bib64","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2010-12-327536","article-title":"Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia","volume":"118","author":"Marsh","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e38460_bib66","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-981-32-9717-3_3","article-title":"The TNF-TNFR family of Co-signal molecules","volume":"1189","author":"So","year":"2019","journal-title":"ADV EXP MED BIOL"},{"key":"10.1016\/j.heliyon.2024.e38460_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1360275","article-title":"Remission of relapsed\/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report","volume":"15","author":"Giannotti","year":"2024","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38460_bib68","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.bbmt.2020.02.003","article-title":"Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapse\/refractory Hodgkin lymphoma: real-life experience in Spain","volume":"26","author":"Martinez","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38460_bib69","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e38460_bib72","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2017-03-772210","article-title":"Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease","volume":"129","author":"Chen","year":"2017","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.heliyon.2024.e38460_bib74","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood-2015-09-668145","article-title":"Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice","volume":"127","author":"Jin","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38460_bib75","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2011-07-364414","article-title":"Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans","volume":"119","author":"Srinivasan","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib76","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-10-1198","article-title":"Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation","volume":"17","author":"Tawara","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e38460_bib77","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","article-title":"Tocilizumab (actemra)","volume":"13","author":"Sheppard","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38460_bib78","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/imcb.12652","article-title":"Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide","volume":"101","author":"Sligar","year":"2023","journal-title":"Immunol. Cell Biol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38460_bib79","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38460_bib80","first-page":"511","article-title":"Tocilizumab for cytokine release syndrome management after haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"29","author":"Yao","year":"2023","journal-title":"TRANSPL CELL THER"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38460_bib84","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13576","article-title":"Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD","volume":"23","author":"Mirgh","year":"2021","journal-title":"Transpl. Infect. Dis."},{"issue":"14","key":"10.1016\/j.heliyon.2024.e38460_bib85","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/blood.2020009050","article-title":"A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin\/methotrexate GVHD prophylaxis","volume":"137","author":"Kennedy","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38460_bib86","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41409-018-0236-z","article-title":"Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract","volume":"54","author":"Ganetsky","year":"2019","journal-title":"BONE MARROW TRANSPL"},{"key":"10.1016\/j.heliyon.2024.e38460_bib87","series-title":"Successful Treatment with Intrathecal Tocilizumab (IL-6 Antibody) for 2 Cases of Graft-Versus Host Disease of the Central Nervous System after a Second Allogeneic HSCT from Haploidentical Donor","author":"Gui","year":"2018"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38460_bib88","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood-2016-04-711275","article-title":"TNF-alpha priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment","volume":"128","author":"Pierini","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib89","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int. Immunol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38460_bib90","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1620\/tjem.251.81","article-title":"Successful anti-TNF-alpha therapy for Crohn's disease after allogeneic stem cell transplantation: a case report","volume":"251","author":"Kamachi","year":"2020","journal-title":"Tohoku J. Exp. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e38460_bib91","first-page":"2452","article-title":"[Infliximab therapy for Crohn's-like gastrointestinal lesions after allogeneic bone marrow transplantation]","volume":"56","author":"Onaka","year":"2015","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.heliyon.2024.e38460_bib92","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jdcr.2023.11.003","article-title":"Successful use of dupilumab in recalcitrant pediatric atopic dermatitis-like graft-versus-host disease: a case series","volume":"44","author":"Belmesk","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38460_bib93","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/pde.15146","article-title":"Atopic dermatitis-like graft-versus-host disease treated with dupilumab","volume":"40","author":"Larijani","year":"2023","journal-title":"Pediatr. Dermatol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38460_bib94","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/bjd\/ljad526","article-title":"Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease","volume":"190","author":"Tierney","year":"2024","journal-title":"BRIT J DERMATOL"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib95","first-page":"219","article-title":"Quantitative characterization of the intrinsic ligand-binding affinity of the interleukin 2 receptor beta chain and its modulation by the alpha chain and a second affinity-modulating element","volume":"10","author":"Ringheim","year":"1991","journal-title":"Lymphokine Cytokine Res."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38460_bib96","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1084\/jem.160.4.1126","article-title":"Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen","volume":"160","author":"Robb","year":"1984","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38460_bib97","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/14712598.2010.485187","article-title":"Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation","volume":"10","author":"Campara","year":"2010","journal-title":"Expet Opin. Biol. Ther."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e38460_bib98","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/bmt.2017.100","article-title":"Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia","volume":"52","author":"Zhang","year":"2017","journal-title":"BONE MARROW TRANSPL"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib100","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277307","article-title":"Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: a multi-center prospective study","volume":"6","author":"Tan","year":"2017","journal-title":"OncoImmunology"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38460_bib101","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ajh.25839","article-title":"Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: updated experience from a large-scale study","volume":"95","author":"Liu","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e38460_bib102","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-12-290403","article-title":"Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new","volume":"117","author":"Coghill","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e38460_bib103","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood-2012-09-378653","article-title":"Essentials of Th17 cell commitment and plasticity","volume":"121","author":"Muranski","year":"2013","journal-title":"Blood"},{"issue":"5969","key":"10.1016\/j.heliyon.2024.e38460_bib104","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1178334","article-title":"Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells","volume":"327","author":"O'Shea","year":"2010","journal-title":"SCIENCE"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib105","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.4049\/jimmunol.1400973","article-title":"Anti-IL-12\/23 p40 antibody attenuates experimental chronic graft-versus-host disease via suppression of IFN-gamma\/IL-17-producing cells","volume":"194","author":"Okamoto","year":"2015","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38460_bib106","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1182\/blood.2020005170","article-title":"Retinoic acid-responsive CD8 effector T cells are selectively increased in IL-23-rich tissue in gastrointestinal GVHD","volume":"137","author":"Ball","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib107","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3324\/haematol.2017.171199","article-title":"In vivo IL-12\/IL-23p40 neutralization blocks Th1\/Th17 response after allogeneic hematopoietic cell transplantation","volume":"103","author":"Pidala","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38460_bib108","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jid.2020.09.033","article-title":"IFN-\u7eac-Stimulated apoptotic keratinocytes promote sclerodermatous changes in chronic graft-versus-host disease","volume":"141","author":"Saito","year":"2021","journal-title":"J. Invest. Dermatol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38460_bib109","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood.2023023291","article-title":"The brain may devise laws for the blood","volume":"143","author":"Ritchie","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib110","doi-asserted-by":"crossref","DOI":"10.1172\/JCI125986","article-title":"IFN-\u03b3R\/STAT1 signaling in recipient hematopoietic antigen-presenting cells suppresses graft-versus-host disease","volume":"133","author":"Lu","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.heliyon.2024.e38460_bib111","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood-2023-181096","article-title":"Emapalumab for treatment of impending graft failure","volume":"142","author":"Sabulski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e38460_bib112","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev.immunol.21.120601.140946","article-title":"CD45: a critical regulator of signaling thresholds in immune cells","volume":"21","author":"Hermiston","year":"2003","journal-title":"Annu. Rev. Immunol."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e38460_bib113","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1182\/blood.2023023549","article-title":"Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate-conditioned Fanconi anemia mice","volume":"143","author":"Saha","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e38460_bib114","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.omtm.2020.02.001","article-title":"Effective multi-lineage engraftment in a mouse model of Fanconi anemia using non-genotoxic antibody-based conditioning","volume":"17","author":"Srikanthan","year":"2020","journal-title":"MOL THER-METH CLIN D"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib115","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jid.2023.08.026","article-title":"Sclerotic-type cutaneous chronic graft-versus-host disease exhibits activation of T helper 1 and OX40 cytokines","volume":"144","author":"Kim","year":"2024","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib116","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38460_bib117","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.2023022040","article-title":"CSF1R inhibition promotes neuroinflammation and behavioural deficits during graft-versus-host disease in mice","volume":"143","author":"Adams","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e38460_bib118","unstructured":"Cauvin A, Wang L, Mason S: Targeting Colony Stimulating Factor-1 Receptor (CSF-1R) with SNDX-6352, a Novel Anti-CSF-1r Targeted Antibody."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38460_bib120","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jtct.2023.12.060","article-title":"Safety and efficacy of axatilimab in patients with chronic graft-versus-host disease (AGAVE-201)","volume":"30","author":"DeFilipp","year":"2024","journal-title":"Transplantation and Cellular Therapy"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38460_bib121","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0092-8674(00)80438-9","article-title":"Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion","volume":"91","author":"Imai","year":"1997","journal-title":"CELL"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38460_bib122","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1084\/jem.188.8.1413","article-title":"Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow","volume":"188","author":"Fong","year":"1998","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib123","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13075-024-03307-8","article-title":"Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model","volume":"26","author":"Hasegawa","year":"2024","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2018.08.008","article-title":"Quantity and quality reconstitution of NKG2A(+) natural killer cells are associated with graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"25","author":"Hu","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.heliyon.2024.e38460_bib125","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood-2021-150730","article-title":"Safety of anti-nkg2a blocking antibody monalizumab as maintenance therapy after allogeneic hematopoietic stem cell transplantation: a phase I study","volume":"138","author":"Devillier","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib126","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/TP.0000000000002941","article-title":"Alterations in NKG2A and NKG2C subsets of natural killer cells following epstein-barr virus reactivation in CTLA4Ig-based haploidentical transplantation is associated with increased chronic graft-versus-host disease","volume":"104","author":"Jaiswal","year":"2020","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib127","doi-asserted-by":"crossref","first-page":"565","DOI":"10.14309\/ajg.0000000000002552","article-title":"Adalimumab vs infliximab in luminal pediatric Crohn's disease: comparable outcomes in a prospective multicenter cohort study","volume":"119","author":"DeBruyn","year":"2024","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38460_bib128","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/MIB.0000000000001021","article-title":"Long-term efficacy and safety of adalimumab in pediatric patients with Crohn's disease","volume":"23","author":"Faubion","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.heliyon.2024.e38460_bib129","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/ecco-jcc\/jjae013","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis through 5 Years in Crohn\u2019s disease and 4 Years in ulcerative colitis","volume":"7","author":"Ghosh","year":"2024","journal-title":"J CROHNS COLITIS18"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJMc1915042","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"382","author":"Rowan","year":"2020","journal-title":"NEW ENGL J MED"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38460_bib131","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.heliyon.2024.e38460_bib141","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"GASTROENTEROLOGY"},{"issue":"12 Suppl 9","key":"10.1016\/j.heliyon.2024.e38460_bib132","first-page":"2","article-title":"Early symptomatic improvement with guselkumab induction treatment in moderately to severely active ulcerative colitis: results from the phase 3 QUASAR study","volume":"19","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38460_bib133","first-page":"307","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"LANCET GASTROENTEROL"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e38460_bib134","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00296-024-05589-2","article-title":"Belimumab corticosteroid-sparing treatment in systemic lupus erythematosus: a real-life observational study (BESST study)","volume":"44","author":"Jais","year":"2024","journal-title":"Rheumatol. Int."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38460_bib135","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.heliyon.2024.e38460_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108402","article-title":"The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases","volume":"102","author":"Berry","year":"2022","journal-title":"INT IMMUNOPHARMACOL"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38460_bib137","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","article-title":"Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study","volume":"80","author":"Paul","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38460_bib138","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2023.02.061","article-title":"Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: analysis of a single-arm, open-label, phase 1 trial","volume":"89","author":"Fukasawa","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38460_bib139","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"LANCET RESP MED"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38460_bib140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American thoracic society clinical practice guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"AM J RESP CRIT CARE"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402414491X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402414491X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:44:46Z","timestamp":1789821886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402414491X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":141,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S240584402414491X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38460","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances and research progress regarding monoclonal antibodies for chronic graft-versus-host disease","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e38460"}}